Biopharmaceutical News and Research

RSS

Aegerion third quarter net loss increases to $6.2 million

Aegerion Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights for the third quarter ended September 30, 2010.

30 Nov 2010

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway.

30 Nov 2010

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Quintiles, the world's leading biopharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

30 Nov 2010

SDI and CSD announce launch of oncology therapeutic market research service

SDI and Cegedim Strategic Data (CSD) announced today that they will jointly launch a new market research service that tracks selling activities in the oncology therapeutic market. The Oncology Selling Audit will be released in January 2011; 2 years of history will be available for reporting and analysis.

30 Nov 2010

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

30 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

CQDM and Alsace BioValley enter long term research collaboration

Alsace BioValley, a French competitive health cluster dedicated to therapeutic innovation and CQDM (Québec Consortium for Drug Discovery) sign in Paris today an agreement on a bilateral partnership for the benefit of Alsatian and Quebec research centers and industries in the life sciences and health sector.

26 Nov 2010

Study on using Public Relations to launch, grow and extend brands throughout a product's lifecycle

Traditionally, Public Relations has served as a limited marketing tool for generating brand awareness and reaching consumers. More recently, the reach and potential of Public Relations has greatly expanded through technologies such as Web sites, online social networks, information alerts and blogs. Meanwhile, traditional media sources continue to play an important role.

25 Nov 2010

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.

24 Nov 2010

ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone

Idenix Pharmaceuticals, Inc, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the Company will receive a payment of $20 million from the ViiV Healthcare Company for the achievement of a clinical milestone relating to GSK2248761.

23 Nov 2010

Compugen announces development of Protein Family Members Discovery Platform

Compugen Ltd. announced today the development of its Protein Family Members Discovery Platform, designed for the discovery of novel protein members belonging to various known and clinically important protein families.

23 Nov 2010

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office has granted patent #7,829,668, entitled Compositions and methods for modifying toxic effects of proteinaceous compounds.

22 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

Researchers to discuss latest advances in Alzheimer's research

Today, America's biopharmaceutical research companies highlighted the 98 new medicines in the pipeline for Alzheimer's disease and other dementias, either in clinical trials or awaiting FDA review.

20 Nov 2010

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that the Company will present new data at the American Society of Nephrology meeting being held in Denver, Colorado, on its late-stage investigational drug Soluble Ferric Pyrophosphate, which is being studied for the treatment of iron-deficiency anemia in ESRD patients.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

CMS grants Qutenza J-code to NeurogesX

NeurogesX, Inc. a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a unique, Level II Health Care Common Procedural Coding System (Level II HCPCS), commonly referred to as a J-code, for Qutenza (capsaicin) 8% patch.

19 Nov 2010

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

From Baxter International Inc. 19 Nov 2010

Biopharmaceutical News and Research

Aegerion third quarter net loss increases to $6.2 million

GeoVax supports Bionor's Phase 2b trial of therapeutic HIV/AIDS vaccine

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

SDI and CSD announce launch of oncology therapeutic market research service

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

CQDM and Alsace BioValley enter long term research collaboration

Study on using Public Relations to launch, grow and extend brands throughout a product's lifecycle

Provectus reports progress in PV-10 program for metastatic melanoma

ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone

Compugen announces development of Protein Family Members Discovery Platform

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Researchers to discuss latest advances in Alzheimer's research

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

CMS grants Qutenza J-code to NeurogesX

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

How to optimize your cell line development eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News